A retrospective analysis to examine factors associated with mortality in Medicare beneficiaries newly diagnosed with multiple myeloma

References

• Avet-Loiseau H, Corre J. Pathophysiology. In: Mohty M, Harousseau JL, eds. Handbook of Multiple Myeloma, 1st edn. Switzerland: Springer International Publishing, 2015:1-13
   Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Eng J Med 2007;356:2582-90
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993-9
   PubMed Web of Science ®Google Scholar
• Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008;111:2521-6
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Kumar SR, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122-8
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER Stat Fact Sheets: Myeloma. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html [Last accessed 11 April 2016]
   Google Scholar
• Aviles A, Neri N, Huerta-Guzman J, Nambo MJ. Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation. Curr Oncol 2013;20:e13-20
   PubMed Web of Science ®Google Scholar
• Ria R, Reale A, Moschetta M, et al. A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents. Int J Clin Exp Med 2013;6:30-8
   PubMed Web of Science ®Google Scholar
• Wahlin A, Holm J, Nyström L. Improved survival in multiple myeloma with combination chemotherapy and plasmapheresis. Haematologia (Budap) 1984;17:465-71
   PubMedGoogle Scholar
• Notario A, Torriani A, Vitti MP, et al. Plasmapheresis and survival of patients with myeloma and secondary renal insufficiency. Minerva Med 1983;74:2861-5
   PubMedGoogle Scholar
• Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-9
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 2014;28:1346-8
   PubMed Web of Science ®Google Scholar
• Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28:830-4
   PubMed Web of Science ®Google Scholar
• Kurtin S, Faiman B. The changing landscape of multiple myeloma: implications for oncology nurses. Clin J Oncol Nurs 2013;17(Suppl):7-11
   PubMed Web of Science ®Google Scholar
• Pulte D, Redaniel MT, Lowry L, et al. Age disparities in survival from lymphoma and myeloma: a comparison between US and England. Br J Haematol 2014;165:824-31
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2007. Bethesda, MD, USA: National Cancer Institute, 2010
   Google Scholar
• Davey Smith G, Neaton JD, Wentworth D, et al. Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Lancet 1998;351:934-9
   PubMed Web of Science ®Google Scholar
• Abou-Jawde RM, Baz R, Walker E, et al. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica 2006;91:1410-13
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population based study. Blood 2010;116:5501-6
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma Version 2.2014. Available at http://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=250 [Last accessed 27 June 2016]
   Google Scholar
• Hebert PL, Geiss LS, Tierney EF, et al. Identifying persons with diabetes using Medicare Claims data. Am J Med Qual 1999;14:270-7
   PubMedGoogle Scholar
• Liu J, Huang Z, Gilbertson DT, et al. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010;77:141-51
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7
   PubMed Web of Science ®Google Scholar
• Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007;24:227-30
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7:1823-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-90
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Bergsagel PL, Pearse RN, et al. The addition of clarithromycin improves response to dexamethasone in chemotherapy naive multiple myeloma patients. Proc Am Soc Clin Oncol 2003;22:582
   Google Scholar